Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized placebo-controlled study of teverelix after first acute urinary retention in men with benign prostatic hyperplasia
2026-525963-41-00Phase 2Authorised
- Sponsor
- Antev
- Start
- Nov 2026
- Modality
- Small Molecules, Peptides
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Teverelix with Placebo (2 arms). Primary endpoint: Percent change in total prostate volume at week 12. Planned start Nov 2026; status: authorised.
02
Drugs
teverelix
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2026-525963-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525963-41-00.